Topiramate
| Status | Commercial |
| Development phase | |
| Therapeutic cat. | Neurology |
| Polymorphic form | Orthorhombic structure |
| CAS No. | 97240-79-4 |
| Reference Product | |
| Injectable Form | |
| EU DMF readiness |  |
| CEP | |
| CHINESE DMF | |
| JAPANESE DMF | |
| KOREAN DMF | |
| CANADIAN DMF | |
| CADIFA | |
| US DMF readiness | |
| OEB No. | |
| Samples |
Drug description
Topiramate is used alone or with other medications to treat certain types of seizures in adults and children at least 2 years old. Some brand forms of topiramate extended-release capsule are used only in adults and children who are at least 6 years old. Topiramate is also used to prevent migraine headaches in adults and children who are at least 12 years old.
Polpharma API
Disclaimer
Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s).
